Informed consent to HIV cure research

被引:20
作者
Bromwich, Danielle [1 ]
Millum, Joseph R. [2 ]
机构
[1] Univ Massachusetts, Dept Philosophy, 100 Morrissey BLVD, Boston, MA 02125 USA
[2] NIH, Clin Ctr Dept Bioeth, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA
关键词
ETHICAL CONSIDERATIONS; TRIALS; INTERVENTIONS; PARTICIPANTS; QUALITY; FORMS;
D O I
10.1136/medethics-2015-103122
中图分类号
B82 [伦理学(道德学)];
学科分类号
摘要
Trials with highly unfavourable risk-benefit ratios for participants, like HIV cure trials, raise questions about the quality of the consent of research participants. Why, it may be asked, would a person with HIV who is doing well on antiretroviral therapy be willing to jeopardise his health by enrolling in such a trial? We distinguish three concerns: first, how information is communicated to potential participants; second, participants' motivations for enrolling in potentially high risk research with no prospect of direct benefit; and third, participants' understanding of the details of the trials in which they enrol. We argue that the communication concern is relevant to the validity of informed consent and the quality of decision making, that the motivation concern does not identify a genuine problem with either the validity of consent or the quality of decision making and that the understanding concern may not be relevant to the validity of consent but is relevant to the quality of decision making. In doing so, we derive guidance points for researchers recruiting and enrolling participants into their HIV cure trials, as well as the research ethics committees reviewing proposed studies.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 33 条
[1]   Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation [J].
Allers, Kristina ;
Huetter, Gero ;
Hofmann, Joerg ;
Loddenkemper, Christoph ;
Rieger, Kathrin ;
Thiel, Eckhard ;
Schneider, Thomas .
BLOOD, 2011, 117 (10) :2791-2799
[2]  
Anderson JL, 2015, AIDS RES HUM RETROV, V31, P36, DOI [10.1089/AID.2014.0236, 10.1089/aid.2014.0236]
[3]  
[Anonymous], 2002, INT ETH GUID BIOM RE
[4]  
[Anonymous], 1995, FIN REP
[5]  
[Anonymous], 2002, RISK COMMUNICATION M
[6]  
[Anonymous], WHAT WOULD YOU DO CU
[7]  
[Anonymous], 2008, DECL HELS ETH PRINC
[8]  
[Anonymous], 1986, Ethics and regulation of clinical research
[9]  
Appelbaum Paul S, 2004, IRB, V26, P1, DOI 10.2307/3564231
[10]  
Beauchamp T. L., 2019, PRINCIPLES BIOMEDICA